After snapping up Parexel with Goldman Sachs, EQT doubles down on healthcare with Life Sciences Partners buyout
After snapping up Parexel with Goldman Sachs, EQT doubles down [...]
Immatics’ cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help?
Immatics’ cell therapy blasts solid tumors in phase 1, but [...]
Startup Regulonix pursues non-opioid pain drug that indirectly blocks a key ion channel
Startup Regulonix pursues non-opioid pain drug that indirectly blocks a [...]
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further blow to hopes for blood cancer target
Novartis dumps 2nd bispecific from $2.6B Xencor pact, dealing further [...]
Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability
Seeking an edge over Amgen, Mirati advances lower KRAS dose [...]
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer
Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse [...]
Gyroscope spins the wheel again as it taps Sanofi for $60M months after ditching IPO attempt
Gyroscope spins the wheel again as it taps Sanofi for [...]
GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca
GSK pulls off clean sweep of endpoint hits in anemia [...]
Blackstone bets on Autolus’ CD19 CAR-T in $250M deal, clearing path to pivotal readout in 2022
Blackstone bets on Autolus’ CD19 CAR-T in $250M deal, clearing [...]
Treating drug-resistant prostate cancer by exploiting tumor-suppressing RNA
Treating drug-resistant prostate cancer by exploiting tumor-suppressing RNA arlene.weintraub Fri, [...]